Page last updated: 2024-12-05

1-amino-2-naphthol-4-sulfonic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

This compound, also known as 1,2-Naphtholsulfonic acid, 4-amino- or 4-Amino-1-hydroxy-2-naphthalenesulfonic acid, is a valuable intermediate in organic synthesis. It is commonly used in the production of dyes, pigments, pharmaceuticals, and other fine chemicals. Its importance stems from its versatile reactivity due to the presence of both amino and hydroxyl groups, along with a sulfonic acid group. The synthesis of 1-amino-2-naphthol-4-sulfonic acid is typically achieved through a series of reactions starting from naphthalene. It has been the subject of research for its diverse applications, including its use as a dye intermediate, antioxidant, and photocatalyst. '

4-amino-3-hydroxynaphthalene-1-sulfonic acid: reagent for removal of chromium(VI) from aqueous solution [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID8316
CHEMBL ID2312198
CHEBI ID19024
SCHEMBL ID153735
MeSH IDM0414610

Synonyms (56)

Synonym
4-amino-3-hydroxy-1-naphthalene sulfonic acid
1-naphthalenesulfonic acid, 4-amino-3-hydroxy-
1-amino-4-sulfo-2-naphthol
116-63-2
4-amino-3-hydroxy-1-naphthalenesulfonic acid
nsc4986
nsc-4986
nsc25061
nsc-25061
CHEBI:19024 ,
1-amino-2-naphthol-4-sulfonic acid
4-amino-3-hydroxynaphthalene-1-sulfonic acid
4-amino-3-hydroxynaphthalene-1-sulphonic acid
einecs 204-147-3
ai3-03701
2-hydroxy-4-sulfo-1-naphthylamine
4-amino-3-hydroxynaphthalenesulfonic acid
1,2,4-acid
nsc 25061
1-naphthalenesulfonic acid,4-amino-3-hydroxy-
4-amino-3-hydroxy-naphthalene-1-sulfonic acid
4-nh2-3-oh-naphthalenesulfonic acid
4-amino-3-hydroxy-1-naphthalenesulfonic acid, acs reagent, >=90%
STK387126
AC-11577
A0367
rxcmfqdtwcclbl-uhfffaoysa-
inchi=1/c10h9no4s/c11-10-7-4-2-1-3-6(7)9(5-8(10)12)16(13,14)15/h1-5,12h,11h2,(h,13,14,15)
AKOS001483109
BBL007892
unii-w46sk3p33g
w46sk3p33g ,
FT-0607319
CHEMBL2312198
SCHEMBL153735
amino-3-hydroxynaphthalenesulfonic acid, 4-
1-amino-2-naphthol-4-sulfonic acid [mi]
DTXSID7059434
4-amino-3-hydroxy-1-napthalenesulfonic acid
RXCMFQDTWCCLBL-UHFFFAOYSA-N
W-108579
1,2,4-aminonaphtholsulfonic acid
naphthalenesulfonic acid, 4-amino-3-hydroxy-
4-amino-3-hydroxy-1-naphthalenesulfonic acid, acs
mfcd00004019
4-amino-3-hydroxy-1-naphthalenesulfonic acid, for spectrophotometric det. of si, >=95.0%
4-amino-3-hydroxy-1-naphthalenesulfonic acid, jis special grade, >=97.0%
D77764
4-amino-3-hydroxy-1-naphthalenesulfonic acid, p.a., 95.0%
2-naphthol-4-sulfonic acid, 1-amino-
Q26840754
AMY22505
FS-4299
CS-W014146
EN300-179895
SY001900
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
mutagenAn agent that increases the frequency of mutations above the normal background level, usually by interacting directly with DNA and causing it damage, including base substitution.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
naphthalenesulfonic acid
aminonaphthalene
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1824261Inhibition of recombinant NDM-1 (unknown origin) using fluorocillin as substrate at 10 uM incubated for 30 mins by fluorescence based assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID1824262Inhibition of recombinant NDM-1 (unknown origin) using fluorocillin as substrate at 3 uM incubated for 30 mins by fluorescence based assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID1824260Inhibition of recombinant NDM-1 (unknown origin) using fluorocillin as substrate at 30 uM incubated for 30 mins by fluorescence based assay2022European journal of medicinal chemistry, Jan-15, Volume: 228Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
AID723759Inhibition of human recombinant cathepsin B endopeptidase activity using Z-Arg-Arg-AMC substrate2013Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
Development of new cathepsin B inhibitors: combining bioisosteric replacements and structure-based design to explore the structure-activity relationships of nitroxoline derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (42.86)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (42.86)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.22 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index51.83 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]